{
    "clinical_study": {
        "@rank": "143001", 
        "arm_group": [
            {
                "arm_group_label": "Delafloxacin", 
                "arm_group_type": "Experimental", 
                "description": "300mg iv Q12H for 6 doses, 450mg oral tablet Q12H for up to 10 - 28 doses total"
            }, 
            {
                "arm_group_label": "Vancomycin plus Aztreonam", 
                "arm_group_type": "Active Comparator", 
                "description": "Vancomycin 15mg/kg iv plus two grams Aztreonam every 12 hours for up to 10 to 28 doses"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus\n      Aztreonam in the treatment of patients with complicated bacterial and soft tissue\n      infections."
        }, 
        "brief_title": "Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Bacterial Skin Infection", 
            "Skin Structure Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Skin Diseases, Infectious", 
                "Skin Diseases, Bacterial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult (\u2265 18 years of age) men or women with a diagnosis of ABSSSI\n             (cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection)\n             with at least two signs of systemic infection\n\n          -  In the opinion of the investigator, the subject must require and be a suitable\n             candidate for IV antibiotic therapy, and the subject must be able and willing to\n             comply with protocol requirements\n\n        Exclusion Criteria:\n\n          -  A medical history of significant hypersensitivity or allergic reaction to quinolones,\n             beta-lactams, vancomycin, or vancomycin derivatives according to the judgment of the\n             investigator.\n\n          -  Women who are pregnant or lactating.\n\n          -  Any chronic or underlying skin condition at the site of infection that may complicate\n             the assessment of response, including infection involving a prosthetic joint, human\n             or animal bite, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic\n             arthritis, mediastinitis, necrotizing fasciitis, anaerobic cellulitis, or synergistic\n             necrotizing cellulitis, myositis, tendinitis, endocarditis, sustained shock, gangrene\n             or gas gangrene; burns covering \u226510% of body surface area; severely compromised\n             immune system, severely impaired arterial blood supply to an extremity with an\n             ABSSSI, deep vein thrombosis or superficial thrombophlebitis, and requiring either an\n             amputation or multiple debridement procedures.\n\n          -  Any underlying disease that, in the opinion of the investigator, could interfere with\n             the subject's ability to participate in the study including severe cardiac disease,\n             known history of liver disease, end-stage renal disease, malignancy, psychiatric\n             disorder, ongoing treatment for seizures or untreated history of seizures, or life\n             expectancy of < 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "660", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984684", 
            "org_study_id": "RX-3341-303"
        }, 
        "intervention": [
            {
                "arm_group_label": "Delafloxacin", 
                "description": "1", 
                "intervention_name": "delafloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vancomycin plus Aztreonam", 
                "description": "2", 
                "intervention_name": "vancomycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Aztreonam", 
                "Vancomycin", 
                "Fluoroquinolones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bacterial skin infection", 
            "infection", 
            "skin", 
            "delafloxacin", 
            "vancomycin", 
            "aztreonam", 
            "MRSA bacteria", 
            "bacterial infection", 
            "Anti-Infective Agents"
        ], 
        "lastchanged_date": "November 14, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy and Safety of IV and Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Digital photography of the infection area will be obtained at Screening, Day 1, Day 2, twice on Day 3 (12 hours apart), Day 4, Day 5, End of Treatment, Follow up, and Late Follow up using the equipment provided. The photography will be analyzed for planimetry measurements and used in the objective response assessments.", 
            "measure": "Objective response of \u226520% reduction in lesion erythema area compared to baseline at 48 to 72 hours after initiation of treatment as determined by digital measurements of the leading edge.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at 48 to 72 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Investigator-assessed response of signs and symptoms of infection at the Follow up Visit (EMA primary endpoint)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 14\u00b11"
            }, 
            {
                "measure": "Investigator-assessed response of signs and symptoms of infection in patients with a baseline BMI \u226530 at the Follow up Visit", 
                "safety_issue": "No", 
                "time_frame": "Up to14 \u00b1 1 days after initiation of treatment"
            }, 
            {
                "measure": "Investigator-assessed response of signs and symptoms of infection at the Late Follow-up Visit", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 28"
            }, 
            {
                "measure": "Reduction of erythema of \u226530% at 48 to 72 hours when digital measurements are used", 
                "safety_issue": "No", 
                "time_frame": "at 48 and 72 hrs"
            }, 
            {
                "measure": "Reduction in pain at End of Treatment as measured by ePRO system", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 14"
            }, 
            {
                "measure": "Microbiological response of eradicated (documented or presumed) at the Follow-up Visit in all patients", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 14"
            }
        ], 
        "source": "Melinta Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Melinta Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}